﻿<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article
    xmlns:mml="http://www.w3.org/1998/Math/MathML"
    xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="systematic-review">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">WJCOR</journal-id>
      <journal-title-group>
        <journal-title>World Journal of Cancer and Oncology Research</journal-title>
      </journal-title-group>
      <issn pub-type="epub"></issn>
      <issn pub-type="ppub"></issn>
      <publisher>
        <publisher-name>Science Publications</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.31586/wjcor.2022.498</article-id>
      <article-id pub-id-type="publisher-id">WJCOR-498</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Systematic Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>
          Tight Junctions and Prostate Cancer
        </article-title>
      </title-group>
      <contrib-group>
<contrib contrib-type="author">
<name>
<surname>Soini</surname>
<given-names>Ylermi</given-names>
</name>
<xref rid="af1" ref-type="aff">1</xref>
<xref rid="cr1" ref-type="corresp">*</xref>
</contrib>
      </contrib-group>
<aff id="af1"><label>1</label>Department of Pathology and Forensic Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, School of Medicine, University of Eastern Finland, Cancer Center of Eastern Finland, PO Box 1627, Kuopio FI-70211, Finland</aff>
<author-notes>
<corresp id="c1">
<label>*</label>Corresponding author at: Department of Pathology and Forensic Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, School of Medicine, University of Eastern Finland, Cancer Center of Eastern Finland, PO Box 1627, Kuopio FI-70211, Finland
</corresp>
</author-notes>
      <pub-date pub-type="epub">
        <day>05</day>
        <month>11</month>
        <year>2022</year>
      </pub-date>
      <volume>1</volume>
      <issue>1</issue>
      <history>
        <date date-type="received">
          <day>05</day>
          <month>11</month>
          <year>2022</year>
        </date>
        <date date-type="rev-recd">
          <day>05</day>
          <month>11</month>
          <year>2022</year>
        </date>
        <date date-type="accepted">
          <day>05</day>
          <month>11</month>
          <year>2022</year>
        </date>
        <date date-type="pub">
          <day>05</day>
          <month>11</month>
          <year>2022</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xa9; Copyright 2022 by authors and Trend Research Publishing Inc. </copyright-statement>
        <copyright-year>2022</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p>
        </license>
      </permissions>
      <abstract>
        In this review proteins associated with tight junctions (TJs) is described with an emphasis on prostate cancer. Overall tight junctional proteins do not seem to play a decisive role in prostate carcinoma pathogenesis. Of TJ proteins, expression of some claudins show an association with clinical behaviour of the tumors. Claudin 1 expression appears to be related to a better prognosis partly due to its involvement in EMT abrogation. Claudin 3 and 4 are highly expressed in prostate cancer and their expression is associated with aggressive behaviour. Inhibition of claudin 8 promotes prostate carcinoma invasion and spread but studies are few. CPE has been known to bind to especially claudins 3 and 4 and cause cell lysis. Several experiments with modified CPE have been made in prostate cancer cell lines. Regardless of this effective CPE based human treatment for prostate cancer have not yet been developed.
      </abstract>
      <kwd-group>
        <kwd-group><kwd>Prostate</kwd>
<kwd>Carcinoma</kwd>
<kwd>Claudin</kwd>
<kwd>Tight Junction</kwd>
</kwd-group>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
<title>Tight junctions</title><p>Tight junctions (TJ) are structures connecting adjacent cells and they are located at the apicolateral border of epithelial cells [
<xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref>]. They regulate the paracellular permeability of cells (barrier function) regulating the movement of ions and solutes between adjacents cells in the epithelium and maintain cellular polarity isolating the apicolateral membrane area from the other parts (fence function) so that membrane proteins and lipids from separate membrane areas do not mix with each other [
<xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref>]. In earlier ultrastructural studies defective tight junctional strands have been described in prostate carcinoma cells compared to benign hyperplasia [
<xref ref-type="bibr" rid="R3">3</xref>]. Additionally, freeze fraction electron microscopy showed several isolated short strands which usually were situated away from the main tight junctional complex [
<xref ref-type="bibr" rid="R3">3</xref>].</p>
<p>The proteins forming TJs are divided to single span proteins which include junctional adhesion molecules (JAM), angulin, and members of the superfamily of immunoglobulins, and tetraspan proteins including claudins and TJ associated marvel proteins (TAMPs) [
<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R6">6</xref>]. The latter include occludin, tricellulin or MarvelD2 and Marvel D3 and the protein crumbs homolog 3 which forms a complex with PATJ and Pals1 which are necessary for the development of apico-basal polarity in epithelial cells [4, 5, 6). Tricellulin is a TJ protein present in corner areas where three cells meet [
<xref ref-type="bibr" rid="R7">7</xref>]. It has four transmembrane domains while angulins 1, 2 and 3 which also are present in these areas, are type I transmembrane proteins with one immunoglobulin-like domain [
<xref ref-type="bibr" rid="R8">8</xref>]. </p>
<p>Scaffolding proteins of TJs include ZO1 (Zonula occludens 1), ZO2 and ZO3 proteins, cingulin, cell polarity protein Par3, afadin, and the multi PDZ domain proteins MUPP1 and PAT which mediate signals from TJ structures to the interior of the cell [
<xref ref-type="bibr" rid="R4">4</xref>]. ZO proteins belong to the membrane-associated guanylate kinase (MAGUK) homologue family with guanylate kinase domain, SH-binding domain and PDZ domains [
<xref ref-type="bibr" rid="R9">9</xref>]. ZO proteins have a molecular weight between 195 and 240kDa, and the carboxyterminal part associates with the cytoskeleton [
<xref ref-type="bibr" rid="R9">9</xref>]. With PDZ domains ZO proteins may dimerise with each other and the N-terminal domain associates with tight junctional and cytoplasmic proteins such as occludin [
<xref ref-type="bibr" rid="R9">9</xref>]. The absence of ZO1 and ZO2 proteins leads to an absence of tight junctional structures and a loss of barrier function of cells and leads to embryonic lethality [
<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R9">9</xref>]. ZO proteins evidently recruit claudins and occludin thus taking part in formation of TJs [Otani]. Afadin interacts with JAM A influencing cell motility but also affects the function of TJs [
<xref ref-type="bibr" rid="R6">6</xref>]. ZO1, 2 and 3 have three PDZ domains and claudins bind to ZO1 by its PDZ1 domain [
<xref ref-type="bibr" rid="R8">8</xref>]. Moreover, ZO1 binds JAM A by its PDZ3 domain and to ZO2 by its PDZ2 domain [
<xref ref-type="bibr" rid="R8">8</xref>]. Presence of cytoplasmic and nuclear ZO1 induces expression of vimentin and MMP-14 promoting invasion and EMT [
<xref ref-type="bibr" rid="R9">9</xref>]. It binds to angulin 1 with the PDZ2 domain [
<xref ref-type="bibr" rid="R8">8</xref>].</p>
<p>Cingulin is a 140-160 kDa protein which interacts with its N terminal globular structure with ZO1, ZO2 and ZO3 and myosin and acting filaments [
<xref ref-type="bibr" rid="R9">9</xref>]. The molecule has also a globular COOH terminal unit and a rodlike structure in between [
<xref ref-type="bibr" rid="R9">9</xref>]. The COOH unit also interacts with myosin and ZO3 and the rodlike middle part interacts with a guanine nucleotide exchange factor, GEF-H1, (which is an activator of small GTPase) and acts as a component for dimerization of the molecule [
<xref ref-type="bibr" rid="R9">9</xref>]. Cingulin strengthens tight junctional sealing, and its absence increases expression of occludin, ZO3 and claudins 2 and 7 [
<xref ref-type="bibr" rid="R9">9</xref>]. Tight junctional structures are preserved in mice with knockdown of cingulin [
<xref ref-type="bibr" rid="R9">9</xref>].</p>
<p>Angulin is present in tricellular junctions and recruits tricellulin to these locations [
<xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R10">10</xref>]. Interestingly, knockdown of angulin 1 destroyed the 10nm tricellular contacts, but they were not affected in case of tricellulin knockdown [
<xref ref-type="bibr" rid="R8">8</xref>]. These contacts were also retained in quinclaudin (lacking claudins 1, 2, 3, 4 and 7) knockdown or JAM A knockdown indicating that angulin 1 is responsible for the barrier function in tricellular junctions [
<xref ref-type="bibr" rid="R8">8</xref>]. In colon carcinoma cell lines knockdown of angulin 1 (also known as lipolysis-stimulated lipoprotein receptor) results in smaller tumor cell size and promoted apoptosis and necrosis [
<xref ref-type="bibr" rid="R11">11</xref>]. Palmitoylation of amino acid residues is essential for localisation of angulin 1 in tricellular junctions [
<xref ref-type="bibr" rid="R12">12</xref>]. It has been suggested that tricellulin in a similar manner like occludin mediates end to side connections in tight junctional strands which is probably related to their structural similarity [
<xref ref-type="bibr" rid="R8">8</xref>]. The role of angulin 2 and 3 is unclear. Mutations in angulin 1 gene cause intrahepatic cholestasis and lack of the gene in embryonic mice is lethal [
<xref ref-type="bibr" rid="R8">8</xref>]. Lack of angulin 2 causes renal concentrating defects and hearing loss and the latter also occurs in tricellulin deficiency [
<xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R12">12</xref>]. Tricellulin, claudins 3, 4, 7, MarvelD3 and TJP3 show a similar expression pattern in different types of tumor cell lines indicating epithelial differentiation [
<xref ref-type="bibr" rid="R13">13</xref>]. When comparing epithelial differentiation to specific expression of tight junctional proteins correlation to epithelial phenotype of tumors were highest with MarcelD3, claudin 7 and ZO3, and tricellulin had a high correlation too (r=0.773) [
<xref ref-type="bibr" rid="R13">13</xref>]. </p>
<p>Transport of water through an epithelial cell layer can take place by a transcellular or paracellular way [
<xref ref-type="bibr" rid="R10">10</xref>]. Aquaporins are responsible for transcellular pathway while in TJs claudins 2 and 15 regulate water permeability through the paracellular space [
<xref ref-type="bibr" rid="R10">10</xref>]. In tricellular junctions both angulin 1 and tricellulin regulate water permeability depending on whether the renal cell lines are of a tight epithelial (MDCK C7) or intermediate cell type (HT-29/B6) the latter not being affected by the regulation [
<xref ref-type="bibr" rid="R10">10</xref>]. Knockdown of angulin 1 decreases expression of claudin 1, 4 and occludin in MDCK C7 cells but levels of angulin 2 or 3 do not change [
<xref ref-type="bibr" rid="R10">10</xref>]. On the other hand, in HT-29/B6 cells angulin knockdown increased the level of several claudins and water efflux is not affected [
<xref ref-type="bibr" rid="R10">10</xref>]. Treatment of MDCKII cells with staurosporine leads to apoptosis and analysis of protein lysates show that tricellulin is a target of caspases [
<xref ref-type="bibr" rid="R14">14</xref>]. Tricellulin was observed to be degraded three hours after staurosporine treatment [
<xref ref-type="bibr" rid="R14">14</xref>]. The caspase target for cleavage of tricellulin is located at the carboxyterminal part of the molecule and cleavage abolished contact with angulin 1 which was degraded in four fragments due to staurosporine treatment [
<xref ref-type="bibr" rid="R14">14</xref>]. Tricellulin cleavage sites are located at D487 and D441 of which the former is preferred and has to be cleaved first [
<xref ref-type="bibr" rid="R14">14</xref>]. In addition to tricellulin, ZO1, ZO2 and occludin are caspase targets [
<xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R15">15</xref>]. Occludin is cleaved to 31 and 55 kDa fragments after staurosporine treatment [
<xref ref-type="bibr" rid="R15">15</xref>]. Of claudins 1 and 2, claudin 2 showed a 11 kDa cleavage fragment after staurosporine treatment while claudin 1 was not affected [
<xref ref-type="bibr" rid="R15">15</xref>]. ZO1 was degraded to five and ZO2 to three fragments [
<xref ref-type="bibr" rid="R15">15</xref>].</p>
</sec><sec id="sec2">
<title>Junctional adhesion molecules</title><p>The JAMs (junctional adhesion molecules) include JAM A, B, C and JAM4 which display a 15-36 % amino acid homology with each other and belong to a part of a larger entity of cell surface immunoglobulin-like molecules [
<xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R17">17</xref>,<xref ref-type="bibr" rid="R18">18</xref>]. These proteins exist only in vertebrates [
<xref ref-type="bibr" rid="R4">4</xref>]. In addition to barrier function they take part in interepithelial leucocyte migration [
<xref ref-type="bibr" rid="R18">18</xref>]. There are also other immunoglobulin-related proteins such as JAML, CAR, CLMP, ESAM, Coxsackie- and Adenovirus Receptor (CAR) and CAR-like membrane protein (CLMR) [
<xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R4">4</xref>]. JAM A, B, C and JAM4 are expressed in many cell types, and they are present in epithelial and endothelial barriers, cells of the male reproductive system, and cells of the central and peripheral nervous system [
<xref ref-type="bibr" rid="R17">17</xref>]. JAM A, JAM C, CAR, CLMR and ESAM associate with tight junctional complexes [
<xref ref-type="bibr" rid="R4">4</xref>]. The function of TJs is impaired by lack of the extracellular domain of JAM A in epithelial cells [
<xref ref-type="bibr" rid="R4">4</xref>]. JAM A contains two immunoglobulin-like domains, a transmembrane domain, and a cytoplasmic tail [
<xref ref-type="bibr" rid="R6">6</xref>]. Adhesion of JAM A to corresponding molecules of adjacent cells or for cis linkage takes place via the extracellular part [
<xref ref-type="bibr" rid="R6">6</xref>]. JAM A binds to &#x26;#x003b2;2 integrin and LFA-1, JAM B interacts with &#x26;#x003b1;4&#x26;#x003b2;1 integrin, and JAM C acts as a counter-receptor for the leukocyte integrin Mac-1 [
<xref ref-type="bibr" rid="R18">18</xref>]. ZO1, ZO2, PAR-3, and MUPP1 belong to the tight junctional scaffolding proteins with which JAM A interacts [
<xref ref-type="bibr" rid="R6">6</xref>]. For a fully developed TJ JAM A needs to be phosphorylated at Ser285 site and JAM A itself recruits molecular components which are needed for development of cellular polarity and TJ formation [
<xref ref-type="bibr" rid="R4">4</xref>]. JAM A, through interaction with scaffolding proteins, influences the actomyosin contractility both in epithelial and endothelial cells which is critical for the barrier function of TJs [
<xref ref-type="bibr" rid="R4">4</xref>]. In epithelial junctions JAM A retains membrane apposition of 6-7 nm and may hinder penetration of larger non-charged solutes through paracellular spaces in the absence of claudins [
<xref ref-type="bibr" rid="R4">4</xref>]. Knockout of JAM A abolishes this macromolecule-involved barrier function from TJs [
<xref ref-type="bibr" rid="R2">2</xref>]. In addition to epithelial or endothelial cells JAM A is also found in leukocytes, Sertoli cells, hematopoietic stem cells, and cells of the nervous system such as glial cells and neuronal progenitor cells and consequently it is involved in various functions such as angiogenesis, hematopoesis, inflammation, immunity and the development of nervous system [
<xref ref-type="bibr" rid="R6">6</xref>]. The cytoplasmic domain in the C-terminal part contains phosphorylation sites and PDZ-binding sites which interact with other proteins making it possible for JAM A to function in different ways [
<xref ref-type="bibr" rid="R6">6</xref>].</p>
<p>JAM A deficient mice develop non-alchoholic steatohepatitis which is due to increased leakiness of gut enterocytes for lipids [
<xref ref-type="bibr" rid="R4">4</xref>]. The expression of JAM A is decreased in chronic inflammation of the colon such as IBD and ulcerative colitis and in experimental dextran sulfate solute induced colitis in mice where phosphorylation of Tyr280 disturbs the interaction of JAM A with Rap2 leading to decreased actomyosin contractility and disturbed TJ barrier function [
<xref ref-type="bibr" rid="R4">4</xref>]. JAM A downregulation also contributes to increased expression of claudins 10 and 15 leading to increased paracellular permeability [
<xref ref-type="bibr" rid="R4">4</xref>]. In lung alveolar cells, depletion of JAM A leads to abrogation of claudin 15 and ZO1 and disturbed distribution of claudins 18 and 4 and ZO2 leading to disposition of oedema formation in the alveoli [
<xref ref-type="bibr" rid="R4">4</xref>]. JAM A has been reported to induce secretion of PSA in association with claudin 7 [
<xref ref-type="bibr" rid="R19">19</xref>]. SNARE (soluble N-ethylmaleimide-sensitive factor associated receptor) proteins are involved in trafficking of proteins from ER and Golgi apparatus to cell membrane [
<xref ref-type="bibr" rid="R20">20</xref>]. Ykt6, one of these proteins, downregulates JAM A expression in prostate carcinoma cell line DU145 resulting in abrogation of cell migration [
<xref ref-type="bibr" rid="R20">20</xref>]. Knockdown of Ykt6 leads to overexpression of JAM A and activation of Rap1 which induces cell motility by &#x26;#x003b2;1-integrin mediated mechanism [
<xref ref-type="bibr" rid="R20">20</xref>]. Rap also activates Rac which stimulates formation of actin rich lamellopodia thus promoting cell migration [
<xref ref-type="bibr" rid="R20">20</xref>]. Ykt6 also appears to control expression of Mir125 which regulates JAM A translation [
<xref ref-type="bibr" rid="R20">20</xref>]. Ykt6 expression appears to vary in different carcinomas being low in prostate cancer [
<xref ref-type="bibr" rid="R20">20</xref>]. </p>
<p>JAM B for its part plays a role in blood brain barrier (BBB) formation [
<xref ref-type="bibr" rid="R4">4</xref>]. Also JAM C appears to contribute to the function of BBB since its abnormal splicing leads to brain hemorrhage and its loss associates with hydrocephalus [
<xref ref-type="bibr" rid="R4">4</xref>]. Evidently it is also present in epithelial cells and is recruited to TJs by ZO1 or Par3 [
<xref ref-type="bibr" rid="R4">4</xref>]. JAM proteins can form homodomers and heterodimers with each other through trans interaction, however, later studies claim that JAM C also forms homophilic tetramers, JAM B forms octamers, and JAM4 forms decamers [
<xref ref-type="bibr" rid="R21">21</xref>,<xref ref-type="bibr" rid="R17">17</xref>]. Favored heterodimers include JAM A and B especially during embryonic development, JAM B and C, and JAM C and JAM4 the latter displaying the strongest strength of interaction [
<xref ref-type="bibr" rid="R17">17</xref>]. JAM B and C help leucocytes penetrate the endothelial barrier, and they can adhere to specific leucocyte integrins [
<xref ref-type="bibr" rid="R21">21</xref>]. JAM C is also present in human hematopoetic stem cells, lymphocytes and platelets [
<xref ref-type="bibr" rid="R21">21</xref>]. KLN205 lung squamous carcinoma cells which do not express JAM C showed decreased proliferation with forced expression of JAM C E66R and K68E mutants and these JAM C mutants also prevented metastasis [
<xref ref-type="bibr" rid="R21">21</xref>]. The mutation affects dimerization with JAM B which declines by 30 % [
<xref ref-type="bibr" rid="R21">21</xref>]. Further analysis showed that dimerization is not necessary for the loss of metastatic capacity [
<xref ref-type="bibr" rid="R21">21</xref>]. The E66R mutation was responsible for reduced migration and K68E mutation for reduced metastasis of lung cancer cells [
<xref ref-type="bibr" rid="R21">21</xref>]. KLN205 cells with wild type JAM C produced metastases and the authors concluded that the mutations disturbed cellular polarisation which blocked the capability of the KLN205 cells to form metastases in xerographic mice [
<xref ref-type="bibr" rid="R21">21</xref>]. The mutated cell line induced phosphorylation of p38 MAPK and ERK1/2 after stimulation with the growth factor EGF and, surprisingly, induced expression of snail, LEF1 and ADAM10 contrary to the wild type [
<xref ref-type="bibr" rid="R21">21</xref>]. JAM C has also been shown to promote metastasis in HT1080 fibrosarcoma cells [
<xref ref-type="bibr" rid="R18">18</xref>]. JAM A or JAM C are not related to survival in prostate cancer, but high expression of JAM C is an unfavourable sign in urothelial and renal cancer.</p>
</sec><sec id="sec3">
<title>Coxsackie and adenovirus receptor</title><p>CAR (coxsackie and adenovirus receptor) can heterodimerise with JAM C and it is found in all kinds of tissues especially testis, brain, heart, lung, liver, pancreas or kidney [
<xref ref-type="bibr" rid="R22">22</xref>,<xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R24">24</xref>]. CAR associated with proteins containing a PDZ domain [
<xref ref-type="bibr" rid="R22">22</xref>]. CAR functions as a receptor for adenoviruses (especially 3 and 5), coxsackieviruses and some other viruses and it is necessary in heart and pancreatic development [
<xref ref-type="bibr" rid="R22">22</xref>]. Because of its function as a receptor for adenovirus it has been used in experiments concerning treatment of cancer with adenovirus vectors. Human CAR is located at chromosome 21 (21q21.1) and it forms splice variants [
<xref ref-type="bibr" rid="R23">23</xref>]. Like other JAM proteins, it contains two extracellular IgG-components needed for dimerization and contains glycosylation and palmitoylation sites in the transmembrane and cytoplasmic areas which influence its function [
<xref ref-type="bibr" rid="R23">23</xref>]. Of stromal proteins, CAR interacts with tenascin-R, agrin and fibronectin, and of other junctional adhesion molecules with JAM C and JAM L, the latter interaction activating the phosphoinositide-3-kinase pathway in T cells which activates cell proliferation and cytokine production [
<xref ref-type="bibr" rid="R23">23</xref>]. C-terminal PDZ domain binds ZO1, MUPP1 and other molecules by which CAR is connected to actin cytoskeleton [
<xref ref-type="bibr" rid="R23">23</xref>]. CAR also strenghtens TJs through trans homodimerization and plays a role in inflammation and immunity [
<xref ref-type="bibr" rid="R23">23</xref>]. Additionally, in tumors, CAR may either promote or suppress tumorigenesis depending on tumor type [
<xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R24">24</xref>]. In prostate cancer and cancer cell lines, the expression of CAR is lower than in normal cells which appear to express it constantly [
<xref ref-type="bibr" rid="R24">24</xref>,<xref ref-type="bibr" rid="R25">25</xref>]. The average expression in prostate cancer is 80 % while in glioblastoma it was 59 % and in lung neuroendocrine carcinoma 58 % [
<xref ref-type="bibr" rid="R26">26</xref>]. The expression is decreased along with a higher Gleason score but is re-established in metastatic sites [
<xref ref-type="bibr" rid="R27">27</xref>]. In urogenital cancer cell lines CAR expressions was shown to be regulated by histone acetylation [
<xref ref-type="bibr" rid="R25">25</xref>]. In line with this cell lines showed increased CAR expression when exposed to histone deacetylase inhibitors [
<xref ref-type="bibr" rid="R25">25</xref>]. The level of CAR expression differs in different cell lines and in prostate cancer cell line PC3 it is low [
<xref ref-type="bibr" rid="R28">28</xref>]. Transfection of CAR into this cell line appeared to diminish proliferation and migration [
<xref ref-type="bibr" rid="R28">28</xref>]. In prostate cell lines ALVA-31, DU-145, and LNCaP histone acetylase treatment increased CAR expression and apoptosis mediated by an adenovirus vector stimulating TRAIL expression [
<xref ref-type="bibr" rid="R29">29</xref>]. A combination of lovastatin with adenoviral-TRAIL vector appears to increase CAR expression and viral intake leading to a significant lowering of tumor growth in xenografic mice compared to adenovirus-TRAIL vector alone [
<xref ref-type="bibr" rid="R30">30</xref>]. With a chimeric mouse-human antibody attempts have been made to treat cancer in xenograft mice with a positive response observed in lung cancer [
<xref ref-type="bibr" rid="R26">26</xref>]. In xenograft mouse models bigenic PSA/CAR+TRAMP mice appeared to obtain a larger adenovirus intake and replication than controls [
<xref ref-type="bibr" rid="R31">31</xref>]. With histone deacetylase inhibitors such as FK228, expression of CAR has been increased in prostate carcinoma cell lines [
<xref ref-type="bibr" rid="R32">32</xref>]. Administration of adenovirus linked to CD40L antigen vaccine followed by FK228 increased adenovirus intake in prostate cell lines [
<xref ref-type="bibr" rid="R32">32</xref>]. However, due to complicating factors such as changes in cell differentiation to neuroendocrine lineage this mode of treatment did not seem effective [
<xref ref-type="bibr" rid="R32">32</xref>].</p>
</sec><sec id="sec4">
<title>Occludin</title><p>Occludin like claudins has four transmembrane domains between two extracellular loops and a cytoplasmic carboxyterminal and aminoterminal end [
<xref ref-type="bibr" rid="R33">33</xref>]. Removing the N-terminal end of occludin removes its sealing properties and the carboxyterminal part is needed for tight junctional assembly and signal transduction and it has a role in intracellular trafficking of ZO1 [
<xref ref-type="bibr" rid="R33">33</xref>,<xref ref-type="bibr" rid="R34">34</xref>]. Extracellular loops have a sealing function and are needed for attachment to the neighbouring cell [
<xref ref-type="bibr" rid="R33">33</xref>]. N-terminus and extracellular regions are important for the TJ sealing/barrier properties, and mutations of occludin cause increased TJ permeability. Transmembrane domains co-operate with claudins, especially claudin 4 and the extracellular loop are important for occludin/tight junctional assembly [
<xref ref-type="bibr" rid="R9">9</xref>]. Carboxyterminal part of the molecule communicates with intracellular protein and takes also part in tight junctional assembly and recruitment of occluding to TJs [
<xref ref-type="bibr" rid="R9">9</xref>]. Occludin has splice variants including one where the fourth transmembrane domain is lacking [
<xref ref-type="bibr" rid="R33">33</xref>]. Consequently, the carboxyterminal part is located extracellularly and ZO1 cannot bind to occludin [
<xref ref-type="bibr" rid="R34">34</xref>]. There also exist splice variants lacking exon 1a or 9 [
<xref ref-type="bibr" rid="R34">34</xref>]. Occludin can be degraded by MMP2/9 and MMP3 which in endothelial cells leads to damaged and leaky BBB and contributes to cerebral edema and hemorrhage in diabetic retinopathy [
<xref ref-type="bibr" rid="R34">34</xref>]. In epithelial cells increased degradation of occludin leads to leakier barriers and increased occludin expression leads to tightening of the paracellular space [
<xref ref-type="bibr" rid="R34">34</xref>,<xref ref-type="bibr" rid="R9">9</xref>]. Forced expression of occludin in skin and cervix carcinoma cells leads to promotion of apoptosis [
<xref ref-type="bibr" rid="R9">9</xref>]. Posttranslational modifications influence occludin function [
<xref ref-type="bibr" rid="R34">34</xref>]. Phosphorylation of especially tyrosine influences interactions with zonula occludens and other tight junctional molecules and affects barrier function with also serine and threonine phosphorylation having its effects [
<xref ref-type="bibr" rid="R34">34</xref>]. Occludin knockdown mice have TJs, but tight junctional stability and barrier function is affected [
<xref ref-type="bibr" rid="R34">34</xref>]. Knockdown mice show growth retardation and reproductive defects and histological changes in various cells such as in intestine. VEGF decreases occludin phosphorylation increasing vascular permeability and high glucose concentration activates VEGF and IGF1 leading to downregulation of occluding and disruption of TJ in retinal cells similar to TGF&#x26;#x003b2; [
<xref ref-type="bibr" rid="R9">9</xref>]. Occludin expression is not related to survival in prostate cancer.</p>
<p></p>
</sec><sec id="sec5">
<title>Claudins</title><p>Claudins are the tight junctional proteins expressed in epithelial, mesothelial and endothelial cells [
<xref ref-type="bibr" rid="R35">35</xref>,<xref ref-type="bibr" rid="R36">36</xref>,<xref ref-type="bibr" rid="R37">37</xref>]. They were discovered when it was shown that their forced expression led to formation of tight junctions in fibroblasts [
<xref ref-type="bibr" rid="R2">2</xref>] . Claudins show tissue specific expression which in a restricted sense can be used in differential diagnosis of tumors [
<xref ref-type="bibr" rid="R35">35</xref>,<xref ref-type="bibr" rid="R36">36</xref>,<xref ref-type="bibr" rid="R37">37</xref>,<xref ref-type="bibr" rid="R38">38</xref>]. As an example of this we showed that claudins 3 and 4 can be used in differential diagnosis between pleural mesothelioma and metastatic adenocarcinoma to the pleura [
<xref ref-type="bibr" rid="R37">37</xref>]. In Paget&#x26;#x02019;s disease of the breast, claudin 3 and 4 can also be used to detect neoplastic cells in the squamous epithelium of the skin [
<xref ref-type="bibr" rid="R35">35</xref>]. Claudin 4 is strongly expressed in intrahepatic cholangiocarcinoma and can in this way be discriminated from hepatocellular carcinoma [
<xref ref-type="bibr" rid="R38">38</xref>]. Claudins are differentially expressed already in tissue specific fibroblastic stem cells where urinary tract bladder epithelial iPSCs differed in their claudin 1, 5 and 7 expression from skin epithelial iPSCs [
<xref ref-type="bibr" rid="R39">39</xref>]. Prostate lineage iPSCs were also analysed but only through their expression of AR and PSA with which they differed from urothelial iPSCs in an early stage [
<xref ref-type="bibr" rid="R39">39</xref>]. </p>
<p>Claudins are situated apicolaterally in epithelial cell membranes and serve as transepithelial barriers which are selective for molecular size and charge [
<xref ref-type="bibr" rid="R40">40</xref>]. They separate apical and basolateral cell membranes from each other and participate in cell growth and differentiation [
<xref ref-type="bibr" rid="R41">41</xref>]. There are 27 members of claudins that are unique in their tissue-specific expression, and their molecular weight range from 20 to 34 kDa [
<xref ref-type="bibr" rid="R41">41</xref>,<xref ref-type="bibr" rid="R42">42</xref>,<xref ref-type="bibr" rid="R43">43</xref>]. Knockdown of claudins 1, 2, 3, 4, and 7 in MDCKII cells at the same time leads to lack of formation of TJs [
<xref ref-type="bibr" rid="R2">2</xref>]. Lipids and cholesterol also play part in TJ assembly and tight junctional proteins are palmitoylated which promotes their association with lipid rafts in the cell membrane [
<xref ref-type="bibr" rid="R2">2</xref>]. Hypothetically zonula occludens proteins by attaching to tight membrane proteins can then trigger a clustering of tight junctional proteins which, however, is a stepwise and gradual process [
<xref ref-type="bibr" rid="R2">2</xref>]. Claudin attachment to TJs is probably associated with their phosphorylation due to the Par-3/aPKC complex [
<xref ref-type="bibr" rid="R2">2</xref>].</p>
<p>Claudins are transmembrane proteins with two extracellular loops and one intracellular area of 20 protein residues in between [
<xref ref-type="bibr" rid="R41">41</xref>,<xref ref-type="bibr" rid="R9">9</xref>]. The aminoterminal and carboxyterminal sites are intracytoplasmic. There are four domains which perforate the cellular membrane demarcating the extracellular loops from the intracellular part. Thus, the molecule is like a two-wave structure perforating the plasma membrane. The extracellular loops have highly conserved regions with 60 and 24 protein residues [
<xref ref-type="bibr" rid="R9">9</xref>]. Even though the basic structure is like those of tetraspanins, claudins do not belong to this group [
<xref ref-type="bibr" rid="R44">44</xref>,<xref ref-type="bibr" rid="R6">6</xref>]. The loop which is nearest to the aminoterminal part is larger. Claudin function is affected by post-translational modification, mainly phosphorylation which occurs in the carboxyterminal part but there are also some sites for palmitoylation [
<xref ref-type="bibr" rid="R41">41</xref>]. The carboxyterminal part also contains the PDZ motives which mediate signalling to the interior of the cell through the ZO1-3 molecules [
<xref ref-type="bibr" rid="R41">41</xref>]. The larger loop contains the receptor for HCV and the smaller loop for clostridium perfringens toxin (CPE) in claudin types where such areas exit [
<xref ref-type="bibr" rid="R41">41</xref>]. The extracellular segments as well as the transcellular domains are responsible for the side-by-side assembly (cis) as well as head-to-head interactions (trans) of the claudin molecule [
<xref ref-type="bibr" rid="R40">40</xref>]. In claudin 15 residues 39&#x26;#x02013;42 on two opposing (extracellular) ECS1 loops and 146&#x26;#x02013;155 on the ECS2 loops interact to form channels made by eight claudin monomers which are filled with water and ions. The pore diameter is about 6 &#x26;#x000c5; and it is 50 &#x26;#x000c5; long running parallel to the cell membranes, and the pore density is about 300 pores per &#x26;#x000b5;m in tight junctional strands [
<xref ref-type="bibr" rid="R40">40</xref>]. In experiments with claudin 15, certain amino acids at loop sides determine the selectivity of ions, for instance flux of Na+ or K+ through the pore as indicated by experiments with replacing mutations [
<xref ref-type="bibr" rid="R40">40</xref>]. Oxygenated Na + is about 7 &#x26;#x000c5; but interaction of Na+ with oxygen is replaced by interaction with charged amino acids in pores [
<xref ref-type="bibr" rid="R40">40</xref>]. Claudins do not only homodimerize but form heterodimers in both cis and trans positions [
<xref ref-type="bibr" rid="R40">40</xref>,<xref ref-type="bibr" rid="R42">42</xref>]. When keeping in mind the relatively large number of claudins and RNA splicing also taking place in some of them, formation of different kind of pores can be very complex even though all claudins do not exist in same cells. Also, mutation in claudins which affect the binding for instance during heterodimerisation, can modulate pore function [
<xref ref-type="bibr" rid="R40">40</xref>]. Additionally, other factors, such as cholesterol concentration in cell membranes may influence the trans interaction of claudins because the presence of cholesterol reduces trans interactions [
<xref ref-type="bibr" rid="R40">40</xref>].</p>
</sec><sec id="sec6">
<title>Claudins and EMT</title><p>Epitheliomesenchymal transition (EMT) is a process whereby cancer cells invade and metastasise. EMT is triggered by cytokines and growth factors such as transforming growth factor-beta (TGF-&#x26;#x003b2;), epidermal growth factor (EGF) and insulin-like growth factor (IGF), and signaling pathways such as mitogen-activated protein kinase (MAPK) and Phosphatidylinositol 3-Kinase (PI3K) which regulate snail, slug, twist1, twist2 and ZEB1 and ZEB2 transcription factors which in turn regulate epithelial or mesenchymal type genes such as on one hand E-cadherin, occludin and claudins, and on the other hand, vimentin, N-cadherin or &#x26;#x003b1;-smooth muscle actin, respectively [
<xref ref-type="bibr" rid="R45">45</xref>,<xref ref-type="bibr" rid="R43">43</xref>]. Expression of matrix metalloproteinases and their inhibitors are also a part of this process. The opposite process to EMT is mesenchymoepithelial transition (MET) which supposedly occurs when tumor cells start growing and forming epithelial sheets at distant metastatic sites [
<xref ref-type="bibr" rid="R46">46</xref>].</p>
<p>Snail belongs to a family of conservative zinc finger transcription factors [
<xref ref-type="bibr" rid="R47">47</xref>]. Other members of the group are slug and smug [
<xref ref-type="bibr" rid="R47">47</xref>]. Snail transcription factors react with its zinc finger motives with E-box sequences of the target gene promoter or regulatory regions [
<xref ref-type="bibr" rid="R47">47</xref>]. Snail induces the expression of mesenchymal genes, such as vimentin, fibronectin, matrix metalloproteinases MMP2, and MMP9 [
<xref ref-type="bibr" rid="R47">47</xref>]. It has been shown that Snail and slug downregulate claudin 1 [
<xref ref-type="bibr" rid="R48">48</xref>]. There are about 200 HLH transcription factors which can be divided in seven groups [
<xref ref-type="bibr" rid="R49">49</xref>]. Twist1 and 2 belong to group II [
<xref ref-type="bibr" rid="R49">49</xref>]. Twist, Slug, and Snail are associated with aggressive features and disease progression in prostate cancer [
<xref ref-type="bibr" rid="R50">50</xref>]. Twist1 has been shown to downregulate claudin 4 in an esophageal cell line [
<xref ref-type="bibr" rid="R51">51</xref>]. In castrate-resistant prostate carcinoma, VNLG-152, a retinamide compound which interferes with the AR pathway, downregulates slug, snail and twist in tissue xenografts [
<xref ref-type="bibr" rid="R52">52</xref>]. MPRSS2/ERG fusion appears to induce the expression of both ZEB1 and ZEB2 and induce EMT in prostate cancer cells [
<xref ref-type="bibr" rid="R53">53</xref>]. Many of the transcription factors involved in EMT such as snail1, slug, twist1, and ZEB1 are upregulated in prostate cancers with poor prognosis [
<xref ref-type="bibr" rid="R54">54</xref>]. Interestingly, cholesterol lowering rosuvastatin has been shown to downregulate ZEB1 and vimentin in prostate carcinoma PC-3 cell line thus opposing EMT (55). On the other hand, ZEB1 downregulates miR200 which inhibits ETS1, ZEB1 and ZEB2 thus promoting EMT through a positive loop [
<xref ref-type="bibr" rid="R54">54</xref>].</p>
<p>In Caco-2 cells which are colon carcinoma cells claudin 4 appeared to increase the activity of MMP2 and MMP9 thus increasing their invasion [
<xref ref-type="bibr" rid="R56">56</xref>]. A similar association is also present in gastric cancer [
<xref ref-type="bibr" rid="R57">57</xref>]. Similarly, claudin 1 activates MMP2 and MT-MMP1 in oral cancer cell lines resulting in cleavage of laminin &#x26;#x003b3;2 chain [
<xref ref-type="bibr" rid="R58">58</xref>]. Overexpression of claudin 1 in hepatocellular carcinoma also induces MMP2 [
<xref ref-type="bibr" rid="R9">9</xref>]. However, also decreased expression of claudins 1, 4 and 7 may increase invasion in some types of cancer [
<xref ref-type="bibr" rid="R57">57</xref>]. The relation of prostate carcinoma to the complex interaction of claudins to MMPs has not been thoroughly studied.</p>
<p>As components of TJs claudins participate in cell polarity and cellular adhesion [
<xref ref-type="bibr" rid="R41">41</xref>,<xref ref-type="bibr" rid="R43">43</xref>]. In cancer, cellular adhesion is decreased. In line with this many cancers show downregulation of some claudins, such as claudins 1 and 7 [
<xref ref-type="bibr" rid="R41">41</xref>,<xref ref-type="bibr" rid="R43">43</xref>]. On the other hand, expression of some claudins, such as claudins 3 and 4, may be increased in some tumors also in prostate cancer [
<xref ref-type="bibr" rid="R41">41</xref>,<xref ref-type="bibr" rid="R43">43</xref>]. Abrogation of cellular adhesion is a part of EMT. Thus, claudins contribute to this element in tumor spread and probably also to MET even though this has been studied less [
<xref ref-type="bibr" rid="R41">41</xref>]. In prostate cancer elevated levels of ETS1 worsens prognosis [
<xref ref-type="bibr" rid="R54">54</xref>]. Of ETS1 splice variants ETS1p51 is highly expressed in prostate cancer tissues compared to ETS1p42 and the former induces expression of TGF&#x26;#x003b2;mRNA which induces Smad2 phosphorylation and promotes tumor cell migration [
<xref ref-type="bibr" rid="R54">54</xref>]. Through TGF&#x26;#x003b2; ETS1p51 stimulated EMT by inducing ZEB1 mRNA and elevating protein levels of snail and slug leading to downregulation of claudin 1 and upregulation of EMT related genes like vimentin [
<xref ref-type="bibr" rid="R54">54</xref>]. Some ATP sensing P2X and P2Y receptors are activated in prostate cancer and after P2Y2 or P2X7 knockdown extracellular ATP mediated influence on snail, E-cadherin or claudin 1 expression was lost in prostate cancer cell lines [
<xref ref-type="bibr" rid="R59">59</xref>,<xref ref-type="bibr" rid="R60">60</xref>]. Knockdown of P2Y2 or P2X7 receptor decreases snail1 and increased expression of claudin 1 and E-cadherin in tumor cells indicating that it plays a role in prostate cancer EMT [
<xref ref-type="bibr" rid="R59">59</xref>,<xref ref-type="bibr" rid="R60">60</xref>]. Similar to this Ephrin-A2, a ligand for Eph family receptors promotes EMT by upregulating snail, slug, vimentin an N-cadherin and downregulating claudin 1 and E-cadherin in prostate cancer cell lines [
<xref ref-type="bibr" rid="R61">61</xref>].</p>
</sec><sec id="sec7">
<title>Claudins, immunology and scaffolding proteins</title><p>Claudins contribution to immune surveillance is also less studied. Through TJs claudins take part in the formation in development and function of blood brain and blood testis barrier and also contribute to that the eyes are not reached by the immune system [
<xref ref-type="bibr" rid="R62">62</xref>]. They also regulate access of immune mediators to cells [
<xref ref-type="bibr" rid="R7">7</xref>]. Downregulation of claudin 2 in association with starvation increases gut epithelial tightness which is regulated by autophagy associated genes [
<xref ref-type="bibr" rid="R63">63</xref>]. Moreover, TJs prevent gut bacteria from entering the tissues and causing infection [
<xref ref-type="bibr" rid="R63">63</xref>]. On the other hand, claudin 1 is a co-receptor for HCV virus entry to hepatocytes [
<xref ref-type="bibr" rid="R64">64</xref>]. Covid-19 has been reported to destroy the blood testis barrier and downregulate claudin 11 in a study done on autopsy cases [
<xref ref-type="bibr" rid="R65">65</xref>].</p>
<p>Claudins are connected to the cytoskeleton of the cell by scaffolding proteins. The ZO proteins (ZO 1, 2 and 3) are most important for TJs and take part in their assembly [
<xref ref-type="bibr" rid="R66">66</xref>]. Double ZO1/ZO2 knockout cells do not form TJs [
<xref ref-type="bibr" rid="R66">66</xref>]. Claudins are linked to ZO proteins by structural PDZ domains and attachment to tight junctional area also requires ZO protein dimerization [
<xref ref-type="bibr" rid="R66">66</xref>]. The ZO proteins for their part are linked to actin cytoskeleton whereby changes of cytoskeletal tension is mediated to TJs [
<xref ref-type="bibr" rid="R66">66</xref>]. Cingulin and paracingulin are rod-shaped molecules with globular ends and they are found as scaffolding proteins in TJs and adherens junctions [
<xref ref-type="bibr" rid="R66">66</xref>]. They interact with ZO-1, and cingulin also with ZO2, ZO3 and actin microtubules [
<xref ref-type="bibr" rid="R66">66</xref>]. Cingulin and paracingulin also mediate interaction between microtubule and actin filament [
<xref ref-type="bibr" rid="R66">66</xref>]. </p>
</sec><sec id="sec8">
<title>Claudins in prostate cancer</title><p>In mouse prostate tissue, claudins 1 and 7 are located in basolateral cells while claudins 3, 4. 5. 8 and 10 are located apically in the glands [
<xref ref-type="bibr" rid="R67">67</xref>]. In human non-neoplastic prostate at least claudins 1, 3, 4 and 7 are present [
<xref ref-type="bibr" rid="R68">68</xref>]. In the Human protein Atlas, immunohistochemically prostate epithelial cells are positive for claudin 1, 3, 4, 5, 7 (luminal cells positive, basal cells negative), 8, 10, 11, and 12, but expression may vary depending on antibody [
<xref ref-type="bibr" rid="R69">69</xref>]. Claudins 3 and 4 are highly expressed in non-neoplastic prostate and claudin 3 mRNA is detected in acinar cells by in situ hybridisation [
<xref ref-type="bibr" rid="R70">70</xref>]. In some cases, a truncated form of claudin 7 is found in addition to the normal-sized claudin in non-neoplastic prostate tissue [
<xref ref-type="bibr" rid="R70">70</xref>]. In benign prostate hyperplasia the number of TJs is decreased [
<xref ref-type="bibr" rid="R71">71</xref>]. The expression of E-cadherin was decreased in BHPrE1 and BPH-1 prostate hyperplasia epithelial cells leading to an increase in TJ permeability in in vitro experiments [
<xref ref-type="bibr" rid="R71">71</xref>]. TGF-&#x26;#x003b2;1 decreases epithelial barrier function by downregulating claudin 1 in benign prostate hyperplasia which is lower than in normal prostate [
<xref ref-type="bibr" rid="R72">72</xref>]. Claudin 1 in cells of BPH is downregulated by TGF&#x26;#x003b2;1 but snail and slug are upregulated along with increased phosphorylation of ERK1/2 [
<xref ref-type="bibr" rid="R72">72</xref>]. Inhibition of ERK1/2 restored claudin 1 expression while it had no effect on snail or slug [
<xref ref-type="bibr" rid="R72">72</xref>]. </p>
<p>In prostate adenocarcinoma, increased claudin 1 expression associates with a better prognosis [
<xref ref-type="bibr" rid="R73">73</xref>]. Claudin 1 expression was frequently associated with a positive ETS-related gene (ERG) status [
<xref ref-type="bibr" rid="R73">73</xref>]. The ERG-TMPRSS2 fusion is one of the most common genetic alterations in prostate cancer with a frequency of about 50 % [
<xref ref-type="bibr" rid="R74">74</xref>]. Even though mutually present immunohistochemically claudin 4 is not associated to ERG while there is an inverse association between claudin 5 and ERG in prostate cancer and hyperplasia [
<xref ref-type="bibr" rid="R75">75</xref>]. In fact, ERG appears to be involved in claudin 5 gene regulation [
<xref ref-type="bibr" rid="R76">76</xref>]. ERG knockdown, however, leads to decreased expression of claudin 5 in endothelial cells probably reflecting a different path of regulation of claudin 5 in endothelial cells [
<xref ref-type="bibr" rid="R77">77</xref>]. ERG itself is related to more aggressive prostate tumors [
<xref ref-type="bibr" rid="R75">75</xref>]. In prostate cancer gene fusions are also found between TMPRSS2 and ETV1, ETV4, and ETV5 [
<xref ref-type="bibr" rid="R78">78</xref>]. Also, FLI1 can be a member of a fusion protein producing a SLC45A3-FLI1 rearrangement [
<xref ref-type="bibr" rid="R79">79</xref>].</p>
<p>On the other hand, loss of claudin-1 expression is associated with prostate cancer invasion, progression, high grade, biochemical recurrence and metastatic transformation [
<xref ref-type="bibr" rid="R80">80</xref>,<xref ref-type="bibr" rid="R81">81</xref>,<xref ref-type="bibr" rid="R82">82</xref>]. Decreased claudin 1 protein expression independently predicted disease recurrence [
<xref ref-type="bibr" rid="R82">82</xref>]. Seo et al found a high expression of claudin 1 in 54 % of cases and low expression group had a higher Gleason score and higher PSA values [
<xref ref-type="bibr" rid="R81">81</xref>]. While claudin 1 is located in basal cells, its low or negative expression according to some authors can be used as a marker of malignancy in prostate tissue [
<xref ref-type="bibr" rid="R80">80</xref>]. Not surprisingly siRNA inhibition of snail leads to upregulation of claudin1 and E-cadherin in prostate cancer [
<xref ref-type="bibr" rid="R83">83</xref>]. Ephrin-A2 which promotes prostate carcinoma spread downregulates claudin 1 as well as ZO-1 and E-cadherin [
<xref ref-type="bibr" rid="R61">61</xref>]. </p>
<p>In prostate cell lines HGF downregulates expression of claudins 1 and 5 and moves ZO1, ZO2 and ZO3 away from TJ thus disrupting their structure [
<xref ref-type="bibr" rid="R84">84</xref>]. Chemoresistance of prostate carcinoma cell lines were induced by downregulation of E-cadherin and claudin 1 and upregulation of vimentin and snail through notch signaling [
<xref ref-type="bibr" rid="R85">85</xref>]. As TGF&#x26;#x003b2; promotes EMT it upregulates Par-4 (prostate apoptosis response-4) tumor suppressor gene thus leading to phosphorylation of Smad2 and I&#x26;#x003ba;B-&#x26;#x003b1; showing involvement of NF-kB and smad pathways in TGF&#x26;#x003b2;/Par-4 mediated EMT in cancer [
<xref ref-type="bibr" rid="R86">86</xref>]. Prolonged TGF-&#x26;#x003b2;3 exposure leads to downregulation of claudin 1 and E-cadherin, upregulation of snail and vimentin, and silencing of Par-4 by inhibitory RNAs leads to inhibition of TGF&#x26;#x003b2; mediated EMT [
<xref ref-type="bibr" rid="R86">86</xref>]. In this scenario claudin 1 of course acts as only one component of EMT- involved changes reflecting the central role of TGF&#x26;#x003b2; in EMT regulation. Expression of claudins and tight junctional permeability in prostate carcinoma cell line LNCaP appears to be regulated partly by the phosphoinositide 3-kinase (PI3K)/Akt pathway, the inhibition of which leads to claudin upregulation and increase of tight junctional permeability [
<xref ref-type="bibr" rid="R87">87</xref>]. </p>
<p>Weak expression of claudin 2 has been reported in prostate adenocarcinoma [
<xref ref-type="bibr" rid="R88">88</xref>]. Downregulation of Toll like receptor 9 (TLR9) by siRNA results in upregulation of claudin 2 [
<xref ref-type="bibr" rid="R89">89</xref>]. High TLR9 expression was associated with a poor prognosis of the patients [
<xref ref-type="bibr" rid="R89">89</xref>]. Toll like receptors influence claudins at least in other cells. TLR4 ligand upregulates claudin 4 in keratinocytes [
<xref ref-type="bibr" rid="R90">90</xref>]. Interestingly H influenzae and S pneumoniae bacteria induce TLR2 and 4 which downregulate claudin 7 and 10 through upregulation of snail in upper laryngeal epithelium [
<xref ref-type="bibr" rid="R91">91</xref>]. TLRs like TLR3, 4 and 9 are expressed in prostate cancer cells [
<xref ref-type="bibr" rid="R92">92</xref>]. All these observations suggest associations between bacterial infections and tight junctional proteins and their linkage through TLRs. In experiments with mice bacterial infection of the gut has been associated with development of prostate carcinoma [
<xref ref-type="bibr" rid="R93">93</xref>]. </p>
<p>Claudin 3 and 4 function as receptors for clostridium perfingens enterotoxin (CPE) [
<xref ref-type="bibr" rid="R42">42</xref>]. Also, other claudins contain CPE receptors so that claudin-3, -4, -6, -7, and -9 are regarded as high-affinity receptors and claudin-1, -2, -5, -8, -14, and -19 low-affinity receptors, while other claudins do not attach to CPE [
<xref ref-type="bibr" rid="R42">42</xref>]. CPE is known to cause cell death in prostate and ovarian carcinoma cells due to this fact and CPE analogues have been considered promising targets for therapy of prostate and some other cancers [
<xref ref-type="bibr" rid="R94">94</xref>]. The cytotoxity is associated to the N-terminal part of CPE which opens a pore leading to Ca influx in the cell while CPE is recognised by the smaller loop in the C-terminal part [
<xref ref-type="bibr" rid="R95">95</xref>]. The problem of using CPE in treatment is of course that non-malignant cells may also contain CPE binding claudins. Thus modified CPEs have been used in cancer treatment experiments where the molecule has been changed by mutation [
<xref ref-type="bibr" rid="R95">95</xref>]. These mutant CPEs have, however, been targeted on cancers expressing other claudins than claudins 3 or 4, such as claudin 1 in thyroid cancer [
<xref ref-type="bibr" rid="R95">95</xref>]. On the other hand, experimental treatment on claudin 3 expressing colon carcinoma cell lines and animal models with gene transfer experiments have appeared promising [
<xref ref-type="bibr" rid="R96">96</xref>]. The value of CPE associated treatment in cancers, like prostate cancer is, however, still only apparent on an experimental level.</p>
<p>In prostate carcinoma patients, higher serum levels of claudin 3 were detected [
<xref ref-type="bibr" rid="R97">97</xref>]. On the other hand, Worst et al showed that expression of claudin 3 was higher in tumors with Gleason score 8 or higher compared with Gleason score 6-7 or benign prostate hyperplasia [
<xref ref-type="bibr" rid="R98">98</xref>]. In another study expression of claudin-3 correlated with advanced stage tumors and recurrence while expression of claudin 4 correlated with advanced stage [
<xref ref-type="bibr" rid="R82">82</xref>]. Claudin 3 and PTEN were also associated with a positive metastatic status and a higher stage of patients [
<xref ref-type="bibr" rid="R97">97</xref>]. Knockdown of claudin 3 and 4 leads to decreased growth, survival and invasion of prostate adenocarcinoma cells [
<xref ref-type="bibr" rid="R99">99</xref>]. In the study of Launders et al claudin 4 expression was higher in the low Gleason group than high Gleason group (&gt;7) but then also showed higher expression in prostate adenocarcinoma metastatic sites [
<xref ref-type="bibr" rid="R100">100</xref>]. The authors explain the diminished claudin 4 expressions in higher Gleason score group by diminished cohesion and organisation of cells in high grade tumors [
<xref ref-type="bibr" rid="R100">100</xref>]. In another study claudin 4 expression was associated with mean vascular density in prostate cancer [
<xref ref-type="bibr" rid="R101">101</xref>]. Claudin 4 expression was also associated with a high tumor grade, lymphovascular invasion and lymph node metastasis [
<xref ref-type="bibr" rid="R101">101</xref>]</p>
<p>Claudin 2, 3 and 5 expressions are higher in prostate adenocarcinoma compared to prostate hyperplasia while some investigators report lower or higher claudin 4 expressions [
<xref ref-type="bibr" rid="R102">102</xref>,<xref ref-type="bibr" rid="R88">88</xref>]. Claudins 1 and 7 showed a similar level in both conditions while claudin 11 was not detected in prostate epithelial cells [
<xref ref-type="bibr" rid="R102">102</xref>]. Claudin 5, even though present in prostate adenocarcinoma, is characteristically expressed in endothelial cells. Strong claudin 5 expression was found in 65 % of cases and was associated with lower PSA values [
<xref ref-type="bibr" rid="R81">81</xref>]. Patients who are smokers tend to have a worse prognosis of prostate cancer. In a methylome analysis of such patients, claudin 5 (promoter and body areas included) appeared to be one methylated site of ten most frequently methylated genetic regions [
<xref ref-type="bibr" rid="R103">103</xref>]. In prostate cancer cell line PC3, inhibition of methylome preserving enzyme DNMT1, however, leads to increased claudin 3 expression [
<xref ref-type="bibr" rid="R104">104</xref>]. </p>
<p>In a cell line study downregulation of claudin 7, like &#x26;#x003b1;-catenin, appears to be related to aggressive tumor cell types with putative metastatic potential [
<xref ref-type="bibr" rid="R105">105</xref>]. In another study decreased claudin 7 expression in prostate adenocarcinoma was found to be related to high tumor grade [
<xref ref-type="bibr" rid="R82">82</xref>]. Stage specific embryonic antigen 4 (SSEA4) induces EMT and cell migration which is reflected by downregulation of claudin 7 and E-cadherin and upregulation of snail, slug, vimentin, ZEB1 and ZEB2 [
<xref ref-type="bibr" rid="R106">106</xref>]. </p>
<p>Claudin 8 expression is higher in prostate carcinoma than in benign prostate [
<xref ref-type="bibr" rid="R107">107</xref>]. In the promoter region of claudin 8 there are two androgen-sensitive regions, and the expression is blocked by inhibiting the androgen receptor suggesting that it takes part in the regulation of claudin 8 [
<xref ref-type="bibr" rid="R107">107</xref>]. Knockdown of claudin 8 mRNA inhibits prostate cancer proliferation and migration [
<xref ref-type="bibr" rid="R107">107</xref>]. </p>
<p>Claudin 1 expression is downregulated in older males suggesting that an increased transmembrane permeability of prostate epithelial cells may increase inflammation in prostate tissues contributing to prostate hyperplasia [
<xref ref-type="bibr" rid="R108">108</xref>]. The leakiness might contribute to that intraglandular proteins might escape to the intestitium thus recruiting inflammatory T cells and macrophages to the site [
<xref ref-type="bibr" rid="R108">108</xref>]. Similarly age-related lowering of testosterone levels leads to lower expression of claudins 4 and 8 and increased leakiness of epithelial barrier promoting inflammation and an autoimmune humoral response towards prostatic antigens [
<xref ref-type="bibr" rid="R109">109</xref>].</p>
<p></p>
<p></p>
</sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      
<ref id="R1">
<label>[1]</label>
<mixed-citation publication-type="other">Soini Y. Claudins in lung diseases. Respir Res. 2011, 27, 70.
</mixed-citation>
</ref>
<ref id="R2">
<label>[2]</label>
<mixed-citation publication-type="other">Otani T, Furuse M. Tight Junction Structure and Function Revisited. Trends Cell Biol. 2020, 30, 805
</mixed-citation>
</ref>
<ref id="R3">
<label>[3]</label>
<mixed-citation publication-type="other">Sinha AA, Bentley MD, Blackard CE. Freeze-fracture observations on the membranes and junctions in human prostatic carcinoma and benign prostatic hypertrophy. Cancer 1977.40, 1182.
</mixed-citation>
</ref>
<ref id="R4">
<label>[4]</label>
<mixed-citation publication-type="other">Hartmann C, Schwietzer YA, Otani T, Furuse M, Ebnet K. Physiological functions of junctional adhesion molecules (JAMs) in tight junctions. Biochim Biophys Acta Biomembr. 2020, 1862, 183299
</mixed-citation>
</ref>
<ref id="R5">
<label>[5]</label>
<mixed-citation publication-type="other">Matsuda M, Kubo A, Furuse M, Tsukita S. A peculiar internalization of claudins, tight junction-specific adhesion mole-cules, during the intercellular movement of epithelial cells. J Cell Sci. 2004, 117, 1247
</mixed-citation>
</ref>
<ref id="R6">
<label>[6]</label>
<mixed-citation publication-type="other">Steinbacher T, Kummer D, Ebnet K. Junctional adhesion molecule- A: functional diversity through molecular promiscui-ty. Cell Mol Life Sci. 2018, 75, 1393
</mixed-citation>
</ref>
<ref id="R7">
<label>[7]</label>
<mixed-citation publication-type="other">Suzuki T. Regulation of the intestinal barrier by nutrients: The role of tight junctions. Anim Sci J. 2020, 91, e13357.
</mixed-citation>
</ref>
<ref id="R8">
<label>[8]</label>
<mixed-citation publication-type="other">Sugawara T, Furuse K, Otani T, Wakayama T, Furuse M. Angulin-1 seals tricellular contacts independently of tricellulin and claudins. J Cell Biol. 2021, ,220, e202005062
</mixed-citation>
</ref>
<ref id="R9">
<label>[9]</label>
<mixed-citation publication-type="other">Zhang L, Feng T, Spicer LJ. The role of tight junction proteins in ovarian follicular development and ovarian cancer. Re-production. 2018, 155, R183
</mixed-citation>
</ref>
<ref id="R10">
<label>[10]</label>
<mixed-citation publication-type="other">Ayala-Torres C, Krug SM, Rosenthal R, Fromm M. Angulin-1 (LSR) Affects Paracellular Water Transport, However Only in Tight Epithelial Cells. Int J Mol Sci. 2021, 22, 7827
</mixed-citation>
</ref>
<ref id="R11">
<label>[11]</label>
<mixed-citation publication-type="other">Czulkies BA, Mastroianni J, Lutz L, Lang S, Schwan C, Schmidt G, Lassmann S, Zeiser R, Aktories K, Papatheodorou P. Loss of LSR affects epithelial barrier integrity and tumor xenograft growth of CaCo-2 cells. Oncotarget. 2017, 8, 37009
</mixed-citation>
</ref>
<ref id="R12">
<label>[12]</label>
<mixed-citation publication-type="other">Oda Y, Sugawara T, Fukata Y, Izumi Y, Otani T, Higashi T, Fukata M, Furuse M. The extracellular domain of angulin-1 and palmitoylation of its cytoplasmic region are required for angulin-1 assembly at tricellular contacts. J Biol Chem. 2020, 295, 4289
</mixed-citation>
</ref>
<ref id="R13">
<label>[13]</label>
<mixed-citation publication-type="other">Kohn KW, Zeeberg BM, Reinhold WC, Pommier Y. Gene expression correlations in human cancer cell lines define molec-ular interaction networks for epithelial phenotype. PLoS One. 2014, 9, e99269
</mixed-citation>
</ref>
<ref id="R14">
<label>[14]</label>
<mixed-citation publication-type="other">Janke S, Mittag S, Reiche J, Huber O. Apoptotic Fragmentation of Tricellulin. Int J Mol Sci. 2019, 20, 4882
</mixed-citation>
</ref>
<ref id="R15">
<label>[15]</label>
<mixed-citation publication-type="other">Bojarski C, Weiske J, Sch&#x000f6;neberg T, Schr&#x000f6;der W, Mankertz J, Schulzke JD, Florian P, Fromm M, Tauber R, Huber O. The specific fates of tight junction proteins in apoptotic epithelial cells. J Cell Sci. 2004, 117, 2097
</mixed-citation>
</ref>
<ref id="R16">
<label>[16]</label>
<mixed-citation publication-type="other">Lauko A, Mu Z, Gutmann DH, Naik UP, Lathia JD. Junctional Adhesion Molecules in Cancer: A Paradigm for the Di-verse Functions of Cell-Cell Interactions in Tumor Progression. Cancer Res. 2020, 80, 4878
</mixed-citation>
</ref>
<ref id="R17">
<label>[17]</label>
<mixed-citation publication-type="other">Mendoza C, Nagidi SH, Mizrachi D. Molecular Characterization of the Extracellular Domain of Human Junctional Ad-hesion Proteins. Int J Mol Sci. 2021, 22, 3482
</mixed-citation>
</ref>
<ref id="R18">
<label>[18]</label>
<mixed-citation publication-type="other">Fuse C, Ishida Y, Hikita T, Asai T, Oku N. Junctional adhesion molecule-C promotes metastatic potential of HT1080 human fibrosarcoma. J Biol Chem. 2007, 282, 8276
</mixed-citation>
</ref>
<ref id="R19">
<label>[19]</label>
<mixed-citation publication-type="other">Wang Q, Zheng JY, Kreth J, Yan X, Kamata M, Campbell RA, Xie Y, Chiu R, Berenson JR, Shi W, Chen IS, Pang S. Reg-ulation of prostate-specific antigen expression by the junctional adhesion molecule A. Urology. 2009, 73, 1119
</mixed-citation>
</ref>
<ref id="R20">
<label>[20]</label>
<mixed-citation publication-type="other">Naydenov NG, Joshi S, Feygin A, Saini S, Litovchick L, Ivanov AI. A membrane fusion protein, Ykt6, regulates epithelial cell migration via microRNA-mediated suppression of Junctional Adhesion Molecule A. Cell Cycle. 2018 ,17,1812
</mixed-citation>
</ref>
<ref id="R21">
<label>[21]</label>
<mixed-citation publication-type="other">Garrido-Urbani S, Vonlaufen A, Stalin J, De Grandis M, Ropraz P, Jemelin S, Bardin F, Scheib H, Aurrand-Lions M, Im-hof BA. Junctional adhesion molecule C (JAM-C) dimerization aids cancer cell migration and metastasis. Biochim Bio-phys Acta Mol Cell Res. 2018,1865,638
</mixed-citation>
</ref>
<ref id="R22">
<label>[22]</label>
<mixed-citation publication-type="other">Excoffon KJDA. The coxsackievirus and adenovirus receptor, virological and biological beauty. FEBS Lett. 2020,594,1828
</mixed-citation>
</ref>
<ref id="R23">
<label>[23]</label>
<mixed-citation publication-type="other">Ortiz-Zapater E, Santis G, Parsons M. CAR, A key regulator of adhesion and inflammation. Int J Biochem Cell Biol. 2017,89,1
</mixed-citation>
</ref>
<ref id="R24">
<label>[24]</label>
<mixed-citation publication-type="other">Reeh M, Bockhorn M, G&#x000f6;rgens D, Vieth M, Hoffmann T, Simon R, Izbicki JR, Sauter G, Schumacher U, Anders M. Pres-ence of the coxsackievirus and adenovirus receptor (CAR) in human neoplasms, a multitumour array analysis. Br J Cancer. 2013,109,1848
</mixed-citation>
</ref>
<ref id="R25">
<label>[25]</label>
<mixed-citation publication-type="other">Pong RC, Lai YJ, Chen H, Okegawa T, Frenkel E, Sagalowsky A, Hsieh JT. Epigenetic regulation of coxsackie and ade-novirus receptor (CAR) gene promoter in urogenital cancer cells. Cancer Res. 2003,63,8680
</mixed-citation>
</ref>
<ref id="R26">
<label>[26]</label>
<mixed-citation publication-type="other">Sakamoto S, Inoue H, Kaneko MK, Ogasawara S, Kajikawa M, Urano S, Ohba SI, Kato Y, Kawada M. Generation and evaluation of a chimeric antibody against coxsackievirus and adenovirus receptor for cancer therapy. Cancer Sci. 2019,110,3595
</mixed-citation>
</ref>
<ref id="R27">
<label>[27]</label>
<mixed-citation publication-type="other">Rauen KA, Sudilovsky D, Le JL, Chew KL, Hann B, Weinberg V, Schmitt LD, McCormick F. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma, potential relevance to gene therapy. Cancer Res. 2002,62,3812
</mixed-citation>
</ref>
<ref id="R28">
<label>[28]</label>
<mixed-citation publication-type="other">Okegawa T, Li Y, Pong RC, Bergelson JM, Zhou J, Hsieh JT. The dual impact of coxsackie and adenovirus receptor ex-pression on human prostate cancer gene therapy. Cancer Res. 2000,60,5031
</mixed-citation>
</ref>
<ref id="R29">
<label>[29]</label>
<mixed-citation publication-type="other">VanOosten RL, Earel JK Jr, Griffith TS. Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis. 2007,12,561
</mixed-citation>
</ref>
<ref id="R30">
<label>[30]</label>
<mixed-citation publication-type="other">Liu Y, Chen L, Gong Z, Shen L, Kao C, Hock JM, Sun L, Li X. Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells. Oncotarget. 2015,6,3055.
</mixed-citation>
</ref>
<ref id="R31">
<label>[31]</label>
<mixed-citation publication-type="other">Bao Y, Peng W, Verbitsky A, Chen J, Wu L, Rauen KA, Sawicki JA. Human coxsackie adenovirus receptor (CAR) ex-pression in transgenic mouse prostate tumors enhances adenoviral delivery of genes. Prostate. 2005,64,401
</mixed-citation>
</ref>
<ref id="R32">
<label>[32]</label>
<mixed-citation publication-type="other">Danielsson A, Dzojic H, Rashkova V, Cheng WS, Essand M. The HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replication. PLoS One. 2011,6,e14700
</mixed-citation>
</ref>
<ref id="R33">
<label>[33]</label>
<mixed-citation publication-type="other">Feldman GJ, Mullin JM, Ryan MP. Occludin, structure, function and regulation. Adv Drug Deliv Rev. 2005,57,883
</mixed-citation>
</ref>
<ref id="R34">
<label>[34]</label>
<mixed-citation publication-type="other">Cummins PM. Occludin, one protein, many forms. Mol Cell Biol. 2012,32,242
</mixed-citation>
</ref>
<ref id="R35">
<label>[35]</label>
<mixed-citation publication-type="other">Soini Y. Claudins 2, 3, 4, and 5 in Paget's disease and breast carcinoma. Hum Pathol. 2004,35,1531
</mixed-citation>
</ref>
<ref id="R36">
<label>[36]</label>
<mixed-citation publication-type="other">Soini Y. Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology. 2005,46,551
</mixed-citation>
</ref>
<ref id="R37">
<label>[37]</label>
<mixed-citation publication-type="other">Soini Y, Kinnula V, Kahlos K, P&#x000e4;&#x000e4;kk&#x000f6; P. Claudins in differential diagnosis between mesothelioma and metastatic adeno-carcinoma of the pleura. J Clin Pathol. 2006,59,250
</mixed-citation>
</ref>
<ref id="R38">
<label>[38]</label>
<mixed-citation publication-type="other">Nishino R, Honda M, Yamashita T, Takatori H, Minato H, Zen Y, Sasaki M, Takamura H, Horimoto K, Ohta T, Nakanuma Y, Kaneko S. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J Hepatol. 2008,49,207
</mixed-citation>
</ref>
<ref id="R39">
<label>[39]</label>
<mixed-citation publication-type="other">Moad M, Pal D, Hepburn AC, Williamson SC, Wilson L, Lako M, Armstrong L, Hayward SW, Franco OE, Cates JM, Fordham SE, Przyborski S, Carr-Wilkinson J, Robson CN, Heer R. A novel model of urinary tract differentiation, tissue regeneration, and disease, reprogramming human prostate and bladder cells into induced pluripotent stem cells. Eur Urol. 2013,64,753
</mixed-citation>
</ref>
<ref id="R40">
<label>[40]</label>
<mixed-citation publication-type="other">Fuladi S, Jannat RW, Shen L, Weber CR, Khalili-Araghi F. Computational Modeling of Claudin Structure and Function. Int J Mol Sci. 2020,21,742
</mixed-citation>
</ref>
<ref id="R41">
<label>[41]</label>
<mixed-citation publication-type="other">Bhat AA, Syed N, Therachiyil L, Nisar S, Hashem S, Macha MA, Yadav SK, Krishnankutty R, Muralitharan S, Al-Naemi H, Bagga P, Reddy R, Dhawan P, Akobeng A, Uddin S, Frenneaux MP, El-Rifai W, Haris M. Claudin-1, A Double-Edged Sword in Cancer. Int J Mol Sci. 2020,21,569
</mixed-citation>
</ref>
<ref id="R42">
<label>[42]</label>
<mixed-citation publication-type="other">Ogbu CP, Roy S, Vecchio AJ. Disruption of Claudin-Made Tight Junction Barriers by Clostridium perfringens Enterotox-in, Insights from Structural Biology. Cells. 2022,11,903.
</mixed-citation>
</ref>
<ref id="R43">
<label>[43]</label>
<mixed-citation publication-type="other">Kyuno D, Takasawa A, Kikuchi S, Takemasa I, Osanai M, Kojima T. Role of tight junctions in the epitheli-al-to-mesenchymal transition of cancer cells. Biochim Biophys Acta Biomembr. 2021,1863,183503
</mixed-citation>
</ref>
<ref id="R44">
<label>[44]</label>
<mixed-citation publication-type="other">Hemler ME. Tetraspanin proteins promote multiple cancer stages. Nat Rev Cancer. 2014,14,49
</mixed-citation>
</ref>
<ref id="R45">
<label>[45]</label>
<mixed-citation publication-type="other">Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT, a multi-tool for tumor progression. EMBO J. 2021,40,e108647
</mixed-citation>
</ref>
<ref id="R46">
<label>[46]</label>
<mixed-citation publication-type="other">Molla MS, Katti DR, Katti KS. In vitro design of mesenchymal to epithelial transition of prostate cancer metastasis using 3D nanoclay bone-mimetic scaffolds. J Tissue Eng Regen Med. 2018,12,727
</mixed-citation>
</ref>
<ref id="R47">
<label>[47]</label>
<mixed-citation publication-type="other">Skrzypek K, Majka M. Interplay among SNAIL Transcription Factor, MicroRNAs, Long Non-Coding RNAs, and Circu-lar RNAs in the Regulation of Tumor Growth and Metastasis. Cancers (Basel). 2020,12,209
</mixed-citation>
</ref>
<ref id="R48">
<label>[48]</label>
<mixed-citation publication-type="other">Mart&#x000ed;nez-Estrada OM, Culler&#x000e9;s A, Soriano FX, Peinado H, Bol&#x000f3;s V, Mart&#x000ed;nez FO, Reina M, Cano A, Fabre M, Vilar&#x000f3; S. The transcription factors Slug and Snail act as repressors of Claudin-1 expression in epithelial cells. Biochem J. 2006,394,449
</mixed-citation>
</ref>
<ref id="R49">
<label>[49]</label>
<mixed-citation publication-type="other">Teng Y, Li X. The roles of HLH transcription factors in epithelial mesenchymal transition and multiple molecular mecha-nisms. Clin Exp Metastasis. 2014,31,367
</mixed-citation>
</ref>
<ref id="R50">
<label>[50]</label>
<mixed-citation publication-type="other">B&#x000f8;rretzen A, Gravdal K, Haukaas SA, Mannelqvist M, Beisland C, Akslen LA, Halvorsen OJ. The epitheli-al-mesenchymal transition regulators Twist, Slug, and Snail are associated with aggressive tumour features and poor outcome in prostate cancer patients. J Pathol Clin Res. 2021,7,253-270.
</mixed-citation>
</ref>
<ref id="R51">
<label>[51]</label>
<mixed-citation publication-type="other">Lee KW, Lee NK, Kim JH, Kang MS, Yoo HY, Kim HH, Um SH, Kim SH. Twist1 causes the transcriptional repression of claudin-4 with prognostic significance in esophageal cancer. Biochem Biophys Res Commun. 2012,423,454.
</mixed-citation>
</ref>
<ref id="R52">
<label>[52]</label>
<mixed-citation publication-type="other">Ramamurthy VP, Ramalingam S, Gediya LK, Njar VCO. The retinamide VNLG-152 inhibits f-AR/AR-V7 and MNK-eIF4E signaling pathways to suppress EMT and castration-resistant prostate cancer xenograft growth. FEBS J. 2018,285,1051
</mixed-citation>
</ref>
<ref id="R53">
<label>[53]</label>
<mixed-citation publication-type="other">Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, Goldfinger N, Loewenthal R, Gazit E, Rotter V, Berger R. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One. 2011,6,e21650
</mixed-citation>
</ref>
<ref id="R54">
<label>[54]</label>
<mixed-citation publication-type="other">Rodgers JJ, McClure R, Epis MR, Cohen RJ, Leedman PJ, Harvey JM, Australian Prostate Cancer BioResource, Thomas MA, Bentel JM. ETS1 induces transforming growth factor &#x003b2; signaling and promotes epithelial-to-mesenchymal transition in prostate cancer cells. J Cell Biochem. 2019,120,848
</mixed-citation>
</ref>
<ref id="R55">
<label>[55]</label>
<mixed-citation publication-type="other">Deezagi A, Safari N. Rosuvastatin inhibit spheroid formation and epithelial-mesenchymal transition (EMT) in prostate cancer PC-3 cell line. Mol Biol Rep. 2020,47,8727
</mixed-citation>
</ref>
<ref id="R56">
<label>[56]</label>
<mixed-citation publication-type="other">Takehara M, Nishimura T, Mima S, Hoshino T, Mizushima T. Effect of claudin expression on paracellular permeability, migration and invasion of colonic cancer cells. Biol Pharm Bull. 2009,32,825-31
</mixed-citation>
</ref>
<ref id="R57">
<label>[57]</label>
<mixed-citation publication-type="other">Hwang TL, Lee LY, Wang CC, Liang Y, Huang SF, Wu CM. Claudin-4 expression is associated with tumor invasion, MMP-2 and MMP-9 expression in gastric cancer. Exp Ther Med. 2010,1,789
</mixed-citation>
</ref>
<ref id="R58">
<label>[58]</label>
<mixed-citation publication-type="other">Oku N, Sasabe E, Ueta E, Yamamoto T, Osaki T. Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res. 2006,66,5251
</mixed-citation>
</ref>
<ref id="R59">
<label>[59]</label>
<mixed-citation publication-type="other">Li WH, Qiu Y, Zhang HQ, Liu Y, You JF, Tian XX, Fang WG. P2Y2 receptor promotes cell invasion and metastasis in prostate cancer cells. Br J Cancer. 2013,109,1666
</mixed-citation>
</ref>
<ref id="R60">
<label>[60]</label>
<mixed-citation publication-type="other">Qiu Y, Li WH, Zhang HQ, Liu Y, Tian XX, Fang WG. P2X7 mediates ATP-driven invasiveness in prostate cancer cells. PLoS One. 2014, 9, e114371.
</mixed-citation>
</ref>
<ref id="R61">
<label>[61]</label>
<mixed-citation publication-type="other">Zhao Y, Cai C, Zhang M, Shi L, Wang J, Zhang H, Ma P, Li S. Ephrin-A2 promotes prostate cancer metastasis by en-hancing angiogenesis and promoting EMT. J Cancer Res Clin Oncol. 2021,147,2013
</mixed-citation>
</ref>
<ref id="R62">
<label>[62]</label>
<mixed-citation publication-type="other">Roudnicky F, Zhang JD, Kim BK, Pandya NJ, Lan Y, Sach-Peltason L, Ragelle H, Strassburger P, Gruener S, Lazendic M, Uhles S, Revelant F, Eidam O, Sturm G, Kueppers V, Christensen K, Goldstein LD, Tzouros M, Banfai B, Modrusan Z, Graf M, Patsch C, Burcin M, Meyer CA, Westenskow PD, Cowan CA. Inducers of the endothelial cell barrier identified through chemogenomic screening in genome-edited hPSC-endothelial cells. Proc Natl Acad Sci U S A. 2020,117,19854
</mixed-citation>
</ref>
<ref id="R63">
<label>[63]</label>
<mixed-citation publication-type="other">Foerster EG, Mukherjee T, Cabral-Fernandes L, Rocha JDB, Girardin SE, Philpott DJ. How autophagy controls the intes-tinal epithelial barrier. Autophagy. 2022,18,86.
</mixed-citation>
</ref>
<ref id="R64">
<label>[64]</label>
<mixed-citation publication-type="other">Gerold G, Moeller R, Pietschmann T. Hepatitis C Virus Entry, Protein Interactions and Fusion Determinants Governing Productive Hepatocyte Invasion. Cold Spring Harb Perspect Med. 2020,10,a036830
</mixed-citation>
</ref>
<ref id="R65">
<label>[65]</label>
<mixed-citation publication-type="other">Peirouvi T, Aliaghaei A, Eslami Farsani B, Ziaeipour S, Ebrahimi V, Forozesh M, Ghadipasha M, Mahmoudiasl GR, Ar-yan A, Moghimi N, Abdi S, Raoofi A, Kargar Godaneh M, Abdollahifar MA. COVID-19 disrupts the blood-testis barrier through the induction of inflammatory cytokines and disruption of junctional proteins. Inflamm Res. 2021,70,1165
</mixed-citation>
</ref>
<ref id="R66">
<label>[66]</label>
<mixed-citation publication-type="other">Rouaud F, Sluysmans S, Flinois A, Shah J, Vasileva E, Citi S. Scaffolding proteins of vertebrate apical junctions, structure, functions and biophysics. Biochim Biophys Acta Biomembr. 2020,1862,183399
</mixed-citation>
</ref>
<ref id="R67">
<label>[67]</label>
<mixed-citation publication-type="other">Sakai N, Chiba H, Fujita H, Akashi Y, Osanai M, Kojima T, Sawada N. Expression patterns of claudin family of tight-junction proteins in the mouse prostate. Histochem Cell Biol. 2007,127,457
</mixed-citation>
</ref>
<ref id="R68">
<label>[68]</label>
<mixed-citation publication-type="other">Shang Y, Cui D, Yi S. Opening tight junctions may be key to opening the blood-prostate barrier. Med Sci Monit. 2014,20,2504
</mixed-citation>
</ref>
<ref id="R69">
<label>[69]</label>
<mixed-citation publication-type="other">Uhlen M, Zhang C, Lee S, Sj&#x000f6;stedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, Sanli K, von Feilitzen K, Oksvold P, Lundberg E, Hober S, Nilsson P, Mattsson J, Schwenk JM, Brunnstr&#x000f6;m H, Glimelius B, Sj&#x000f6;blom T, Edqvist PH, Djureinovic D, Micke P, Lindskog C, Mardinoglu A, Ponten F. A pathology atlas of the human cancer transcrip-tome. Science. 2017,357,eaan2507
</mixed-citation>
</ref>
<ref id="R70">
<label>[70]</label>
<mixed-citation publication-type="other">Martin TA, Mason MD, Jiang WG. HGF and the regulation of tight junctions in human prostate cancer cells. Oncol Rep. 2014,32,213
</mixed-citation>
</ref>
<ref id="R71">
<label>[71]</label>
<mixed-citation publication-type="other">Li F, Pascal LE, Stolz DB, Wang K, Zhou Y, Chen W, Xu Y, Chen Y, Dhir R, Parwani AV, Nelson JB, DeFranco DB, Yo-shimura N, Balasubramani GK, Gingrich JR, Maranchie JK, Jacobs BL, Davies BJ, Hrebinko RL, Bigley JD, McBride D, Guo P, He D, Wang Z. E-cadherin is downregulated in benign prostatic hyperplasia and required for tight junction for-mation and permeability barrier in the prostatic epithelial cell monolayer. Prostate. 2019,79,1226
</mixed-citation>
</ref>
<ref id="R72">
<label>[72]</label>
<mixed-citation publication-type="other">Wang K, Pascal LE, Li F, Chen W, Dhir R, Balasubramani GK, DeFranco DB, Yoshimura N, He D, Wang Z. Tight junc-tion protein claudin-1 is downregulated by TGF-&#x003b2;1 via MEK signaling in benign prostatic epithelial cells. Prostate. 2020,80,1203
</mixed-citation>
</ref>
<ref id="R73">
<label>[73]</label>
<mixed-citation publication-type="other">Kind S, Buscheck F, Hoflmayer D, Hube-Magg C, Kluth M, Tsourlakis MC, Steurer S, Clauditz TS, Luebke AM, Burandt E, Wilczak W, Hinsch A, Dum D, Weidemann S, Fraune C, Beyer B, Steuber T, Huland H, Graefen M, Fisch M, Simon R, Sauter G, Schlomm T, Minner S, Eichenauer T. Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer. World J Urol. 2020,38,2185.
</mixed-citation>
</ref>
<ref id="R74">
<label>[74]</label>
<mixed-citation publication-type="other">Schaefer G, Mosquera JM, Ramoner R, Park K, Romanel A, Steiner E, Horninger W, Bektic J, Ladurner-Rennau M, Rubin MA, Demichelis F, Klocker H. Distinct ERG rearrangement prevalence in prostate cancer, higher frequency in young age and in low PSA prostate cancer. Prostate Cancer Prostatic Dis. 2013,16,132
</mixed-citation>
</ref>
<ref id="R75">
<label>[75]</label>
<mixed-citation publication-type="other">Sz&#x000e1;sz AM, Majoros A, Rosen P, Srivastava S, Dobi A, Szendr&#x00151;i A, Kulka J, Nyir&#x000e1;dy P. Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma. Int Urol Nephrol. 2013,45,727
</mixed-citation>
</ref>
<ref id="R76">
<label>[76]</label>
<mixed-citation publication-type="other">Kalna V, Yang Y, Peghaire CR, Frudd K, Hannah R, Shah AV, Osuna Almagro L, Boyle JJ, G&#x000f6;ttgens B, Ferrer J, Randi AM, Birdsey GM. The Transcription Factor ERG Regulates Super-Enhancers Associated With an Endothelial-Specific Gene Expression Program. Circ Res. 2019,124,1337
</mixed-citation>
</ref>
<ref id="R77">
<label>[77]</label>
<mixed-citation publication-type="other">Yuan L, Le Bras A, Sacharidou A, Itagaki K, Zhan Y, Kondo M, Carman CV, Davis GE, Aird WC, Oettgen P. ETS-related gene (ERG) controls endothelial cell permeability via transcriptional regulation of the claudin 5 (CLDN5) gene. J Biol Chem. 2012,287,6582
</mixed-citation>
</ref>
<ref id="R78">
<label>[78]</label>
<mixed-citation publication-type="other">Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev. 2018,32,1105
</mixed-citation>
</ref>
<ref id="R79">
<label>[79]</label>
<mixed-citation publication-type="other">Paulo P, Barros-Silva JD, Ribeiro FR, Ramalho-Carvalho J, Jer&#x000f3;nimo C, Henrique R, Lind GE, Skotheim RI, Lothe RA, Teixeira MR. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Genes Chromosomes Cancer. 2012,51,240.
</mixed-citation>
</ref>
<ref id="R80">
<label>[80]</label>
<mixed-citation publication-type="other">Krajewska M, Olson AH, Mercola D, Reed JC, Krajewski S. Claudin-1 immunohistochemistry for distinguishing malig-nant from benign epithelial lesions of prostate. Prostate. 2007,67,907
</mixed-citation>
</ref>
<ref id="R81">
<label>[81]</label>
<mixed-citation publication-type="other">Seo KW, Kwon YK, Kim BH, Kim CI, Chang HS, Choe MS, Park CH. Correlation between claudins expression and prognostic factors in prostate cancer. Korean J Urol. 2010,51,239
</mixed-citation>
</ref>
<ref id="R82">
<label>[82]</label>
<mixed-citation publication-type="other">Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS. Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Hum Pathol. 2007,38,564
</mixed-citation>
</ref>
<ref id="R83">
<label>[83]</label>
<mixed-citation publication-type="other">Afkham A, Aghebati-Maleki L, Siahmansouri H, Sadreddini S, Ahmadi M, Dolati S, Afkham NM, Akbarzadeh P, Jadidi-Niaragh F, Younesi V, Yousefi M. Chitosan (CMD)-mediated co-delivery of SN38 and Snail-specific siRNA as a useful anticancer approach against prostate cancer. Pharmacol Rep. 2018,70,418
</mixed-citation>
</ref>
<ref id="R84">
<label>[84]</label>
<mixed-citation publication-type="other">Martin TA, Mason MD, Jiang WG. Tight junctions in cancer metastasis. Front Biosci (Landmark Ed). 2011,16,898
</mixed-citation>
</ref>
<ref id="R85">
<label>[85]</label>
<mixed-citation publication-type="other">Wang W, Wang L, Mizokami A, Shi J, Zou C, Dai J, Keller ET, Lu Y, Zhang J. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Chin J Cancer. 2017,36,35
</mixed-citation>
</ref>
<ref id="R86">
<label>[86]</label>
<mixed-citation publication-type="other">Chaudhry P, Fabi F, Singh M, Parent S, Leblanc V, Asselin E. Prostate apoptosis response-4 mediates TGF-&#x003b2;-induced ep-ithelial-to-mesenchymal transition. Cell Death Dis. 2014,5,e1044.
</mixed-citation>
</ref>
<ref id="R87">
<label>[87]</label>
<mixed-citation publication-type="other">Jeong JW, Jin CY, Park C, Han MH, Kim GY, Moon SK, Kim CG, Jeong YK, Kim WJ, Lee JD, Choi YH. Inhibition of mi-gration and invasion of LNCaP human prostate carcinoma cells by cordycepin through inactivation of Akt. Int J Oncol. 2012,40,1697
</mixed-citation>
</ref>
<ref id="R88">
<label>[88]</label>
<mixed-citation publication-type="other">V&#x000e4;re P, Loikkanen I, Hirvikoski P, Vaarala MH, Soini Y. Low claudin expression is associated with high Gleason grade in prostate adenocarcinoma. Oncol Rep. 2008,19,25
</mixed-citation>
</ref>
<ref id="R89">
<label>[89]</label>
<mixed-citation publication-type="other">Luo Y, Jiang QW, Wu JY, Qiu JG, Zhang WJ, Mei XL, Shi Z, Di JM. Regulation of migration and invasion by Toll-like re-ceptor-9 signaling network in prostate cancer. Oncotarget. 2015,6,22564
</mixed-citation>
</ref>
<ref id="R90">
<label>[90]</label>
<mixed-citation publication-type="other">Kubo T, Sugimoto K, Kojima T, Sawada N, Sato N, Ichimiya S. Tight junction protein claudin-4 is modulated via &#x00394;Np63 in human keratinocytes. Biochem Biophys Res Commun. 2014,455,205
</mixed-citation>
</ref>
<ref id="R91">
<label>[91]</label>
<mixed-citation publication-type="other">Clarke TB, Francella N, Huegel A, Weiser JN. Invasive bacterial pathogens exploit TLR-mediated downregulation of tight junction components to facilitate translocation across the epithelium. Cell Host Microbe. 2011,9,404
</mixed-citation>
</ref>
<ref id="R92">
<label>[92]</label>
<mixed-citation publication-type="other">Zhao S, Zhang Y, Zhang Q, Wang F, Zhang D. Toll-like receptors and prostate cancer. Front Immunol. 2014,5,352
</mixed-citation>
</ref>
<ref id="R93">
<label>[93]</label>
<mixed-citation publication-type="other">Poutahidis T, Cappelle K, Levkovich T, Lee CW, Doulberis M, Ge Z, Fox JG, Horwitz BH, Erdman SE. Pathogenic intes-tinal bacteria enhance prostate cancer development via systemic activation of immune cells in mice. PLoS One. 2013,8,e73933
</mixed-citation>
</ref>
<ref id="R94">
<label>[94]</label>
<mixed-citation publication-type="other">Morin PJ. Claudin proteins in human cancer, promising new targets for diagnosis and therapy. Cancer Res. 2005,65,9603
</mixed-citation>
</ref>
<ref id="R95">
<label>[95]</label>
<mixed-citation publication-type="other">Piontek A, Eichner M, Zwanziger D, Beier LS, Protze J, Walther W, Theurer S, Schmid KW, F&#x000fc;hrer-Sakel D, Piontek J, Krause G. Targeting claudin-overexpressing thyroid and lung cancer by modified Clostridium perfringens enterotoxin. Mol Oncol. 2020,14,261
</mixed-citation>
</ref>
<ref id="R96">
<label>[96]</label>
<mixed-citation publication-type="other">Pahle J, Menzel L, Niesler N, Kobelt D, Aumann J, Rivera M, Walther W. Rapid eradication of colon carcinoma by Clos-tridium perfringens Enterotoxin suicidal gene therapy. BMC Cancer. 2017,17,129.
</mixed-citation>
</ref>
<ref id="R97">
<label>[97]</label>
<mixed-citation publication-type="other">Ye X, Zhao L, Kang J. Expression and significance of PTEN and Claudin-3 in prostate cancer. Oncol Lett. 2019,17,5628
</mixed-citation>
</ref>
<ref id="R98">
<label>[98]</label>
<mixed-citation publication-type="other">Worst TS, von Hardenberg J, Gross JC, Erben P, Schn&#x000f6;lzer M, Hausser I, Bugert P, Michel MS, Boutros M. Data-base-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker. Mol Cell Proteomics. 2017,16,998
</mixed-citation>
</ref>
<ref id="R99">
<label>[99]</label>
<mixed-citation publication-type="other">Liu Q, Shen H, Naguib A, Weiss RM, Martin DT. Knocking down claudin receptors leads to a decrease in prostate can-cer cell migration, cell growth, cell viability and clonogenic cell survival. Mol Biomed. 2021,2,31.
</mixed-citation>
</ref>
<ref id="R100">
<label>[100]</label>
<mixed-citation publication-type="other">Landers KA, Samaratunga H, Teng L, Buck M, Burger MJ, Scells B, Lavin MF, Gardiner RA. Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. Br J Cancer. 2008,99,491
</mixed-citation>
</ref>
<ref id="R101">
<label>[101]</label>
<mixed-citation publication-type="other">Radi DA, Abd-Elazeem MA. Prognostic Significance of Lymphatic Vessel Density Detected by D2-40 and Its Relation to Claudin-4 Expression in Prostatic Adenocarcinoma. Int J Surg Pathol. 2016,24,219
</mixed-citation>
</ref>
<ref id="R102">
<label>[102]</label>
<mixed-citation publication-type="other">Coutinho-Camillo CM, Louren&#x000e7;o SV, da Fonseca FP, Soares FA. Claudin expression is dysregulated in prostate adeno-carcinomas but does not correlate with main clinicopathological parameters. Pathology. 2011,43,143
</mixed-citation>
</ref>
<ref id="R103">
<label>[103]</label>
<mixed-citation publication-type="other">Shui IM, Wong CJ, Zhao S, Kolb S, Ebot EM, Geybels MS, Rubicz R, Wright JL, Lin DW, Klotzle B, Bibikova M, Fan JB, Ostrander EA, Feng Z, Stanford JL. Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes. Cancer. 2016,122,2168
</mixed-citation>
</ref>
<ref id="R104">
<label>[104]</label>
<mixed-citation publication-type="other">Yaqinuddin A, Qureshi SA, Qazi R, Farooq S, Abbas F. DNMT1 silencing affects locus specific DNA methylation and increases prostate cancer derived PC3 cell invasiveness. J Urol. 2009,182,756
</mixed-citation>
</ref>
<ref id="R105">
<label>[105]</label>
<mixed-citation publication-type="other">Morgan C, Jenkins SA, Kynaston HG, Doak SH. The role of adhesion molecules as biomarkers for the aggressive prostate cancer phenotype. PLoS One. 2013,8,e81666
</mixed-citation>
</ref>
<ref id="R106">
<label>[106]</label>
<mixed-citation publication-type="other">Sivasubramaniyan K, Harichandan A, Schilbach K, Mack AF, Bedke J, Stenzl A, Kanz L, Niederfellner G, B&#x000fc;hring HJ. Expression of stage-specific embryonic antigen-4 (SSEA-4) defines spontaneous loss of epithelial phenotype in human solid tumor cells. Glycobiology. 2015,25,902
</mixed-citation>
</ref>
<ref id="R107">
<label>[107]</label>
<mixed-citation publication-type="other">Ashikari D, Takayama KI, Obinata D, Takahashi S, Inoue S. CLDN8, an androgen-regulated gene, promotes prostate cancer cell proliferation and migration. Cancer Sci. 2017,108,1386-1393
</mixed-citation>
</ref>
<ref id="R108">
<label>[108]</label>
<mixed-citation publication-type="other">Pascal LE, Dhir R, Balasubramani GK, Chen W, Hudson CN, Srivastava P, Green A, DeFranco DB, Yoshimura N, Wang Z. Claudin-1 down-regulation in the prostate is associated with aging and increased infiltration of inflammatory cells in BPH. Am J Clin Exp Urol. 2021,9,53-64.
</mixed-citation>
</ref>
<ref id="R109">
<label>[109]</label>
<mixed-citation publication-type="other">Meng J, Mostaghel EA, Vakar-Lopez F, Montgomery B, True L, Nelson PS. Testosterone regulates tight junction proteins and influences prostatic autoimmune responses. Horm Cancer. 2011,2,145
</mixed-citation>
</ref>
    </ref-list>
  </back>
</article>